National consensus statement by the Austrian Societies for Rheumatology, Pulmonology, Infectiology, Dermatology and Gastroenterology regarding the management of latent tuberculosis and the associated utilization of biologic and targeted synthetic disease modifying antirheumatic drugs (DMARDs)
ÖGR, ÖGP, ÖGIT, ÖGDV, ÖGGH · 2022 · Austria
Source and licence
- Authors
- Eva Rath, Michael Bonelli, Christina Duftner et al.
- Title
- National consensus statement by the Austrian Societies for Rheumatology, Pulmonology, Infectiology, Dermatology and Gastroenterology regarding the management of latent tuberculosis and the associated utilization of biologic and targeted synthetic disease modifying antirheumatic drugs (DMARDs)
- Journal
- Wiener Klinische Wochenschrift, 2022
- Licence
- CC BY 4.0
- Changes
- Verbatim excerpts; formatting adapted
Full text retrieved 2026-10-27 from Europe PMC · PMC9684247
Licence statement of the original publication
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
This page reproduces excerpts of the original publication; the original is authoritative. It has not been reviewed by a physician, does not state a recommendation of Medelix and does not replace medical advice. The guideline may have been updated since.
Open the original publication →Full text on Europe PMC
Recommendations
We found no explicitly labelled recommendations in this publication; its recommendations are in the running text of the original.
Abstract
This publication provides a thorough analysis of the most relevant topics concerning the management of latent tuberculosis when using biologic and targeted synthetic Disease Modifying Antirheumatic Drugs (DMARDs) by a multidisciplinary, select committee of Austrian physicians. The committee includes members of the Austrian Societies for Rheumatology and Rehabilitation, Pulmonology, Infectiology, Dermatology and Gastroenterology. Consensus was reached on issues regarding screening and treatment of latent tuberculosis and includes separate recommendations for each biologic and targeted synthetic DMARD.
Contents of the original publication
The section headings of the original.
- Introduction
- Incidence of active tuberculosis and latent tuberculosis
- Mode of action of various b-DMARDs and ts-DMARDs, potential influence on a tuberculosis infection and associated recommendations in the product information of medications (order on the basis of specializations and the date of product placement)
- Existing international recommendations on LTBI and b-DMARDs/ts-DMARDs
- Methods
- Consensus findings
- When should be screened for latent tuberculosis?
- Ahead of which bDMARDs/tsDMARDs should be treated for latent tuberculosis?
- How to screen for latent tuberculosis?
- What is the correct preventive therapy for latent tuberculosis?
- Which protocols should be followed during preventive therapy?
- What to do if preventive therapy is not well tolerated?
- What is the best subsequent procedure upon completion of tuberculosis therapy?
- What to do if IGRA is not conclusive?
- When is it necessary to repeat the IGRA?
- Discussion
A question about this guideline?
Medelix answers clinical questions from guidelines and studies – every statement with its source.
Are you the rights holder and object to this reproduction? Write to contact@medelix.ai and we will take the page down promptly. Imprint